Hyposmia is often not only the first symptom of COVID-19, but its persistence is also a relatively frequent neurological complication of the infection. Little is known about the neural bases of hyposmia persisting after the patient's recovery from COVID-19. Dr Matteo Pardini (University of Genoa, Italy) and colleagues evaluated the presence of regional brain hypometabolism in patients with persistent isolated olfactory dysfunction after recovery from COVID-19. A total of 22 patients underwent whole-body 18F-FDG-PET at least 4 weeks after their recovery, 14 of whom had isolated persistent hyposmia. A voxelwise analysis was used to identify brain regions of relative hypometabolism in patients with hyposmia, compared with 61 healthy controls.
Patients with hyposmia after COVID-19 were characterised by relative hypometabolism in parahippocampal and fusiform gyri in both hemispheres and in left insula compared with controls. Structural connectivity maps showed that the hyposmia cluster was included in the bilateral longitudinal fasciculi, with a probability score of 0.82 and 1.0 for the right and left inferior longitudinal fasciculus, respectively.
“One of the hypotheses to explain hyposmia in COVID-19 patients –in the absence of nasal congestion– is that the virus enters the CNS through the first neurons of the olfactory pathway located in the olfactory mucosa,” Dr Pardini explained. “The present evidence of hypometabolism in two symmetrical, similar regions within the limbic cortex may support the occurrence of a distal involvement of the olfactory pathway. Moreover, the involvement of the inferior longitudinal fasciculus is in line with observations of its role in hyposmia in Parkinson's disease, HIV, and hepatitis C.”
- Pardini M, et al. Brain metabolism and persistent olfactory deficits after SARS-CoV-2 infection: an FDG-PET study. OPR-142, EAN 2021 Virtual Congress, 19–22 June 2021.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Hypersensitivity to uncertainty in subjective cognitive decline Next Article
Pathogenic T-cell signature identified in myasthenia gravis »
« Hypersensitivity to uncertainty in subjective cognitive decline Next Article
Pathogenic T-cell signature identified in myasthenia gravis »
Table of Contents: EAN 2021
Featured articles
Letter from the Editor
COVID-19
First evidence of brainstem involvement in COVID-19
Cognitive/behavioural alterations persistent after COVID-19
Neural base of persistent hyposmia after COVID-19
Neurological symptoms and complications of COVID-19 affect outcomes
Cerebrovascular Disease
Intracerebral haemorrhage only slightly increases mortality in COVID-19 patients
Stroke with covert brain infarction indicates high vascular risk
Expanding precision medicine to stroke care
Dexamethasone not indicated for chronic subdural haematoma
Cognitive Impairment and Dementia
Severe outcomes of COVID-19 in patients with dementia
Promising diagnostic accuracy of plasma GFAP
Sex modulates effect of cognitive reserve on subjective cognitive decline
Hypersensitivity to uncertainty in subjective cognitive decline
Epilepsy
Minimally invasive device to detect focal seizure activity
‘Mozart effect’ in epilepsy: why Mozart tops Haydn
Migraine and Headache
Factors associated with decreased migraine attack risk
Pregnant migraine patients at higher risk of complications
Occipital nerve stimulation in drug-resistant cluster headache
Rhythmicity in primary headache disorders
Multiple Sclerosis and NMOSD
Typing behaviour to remotely monitor clinical MS status
Alemtuzumab in treatment-naïve patients with aggressive MS
No higher early MS relapse frequency after stopping ponesimod
Good long-term safety and efficacy of inebilizumab in NMOSD
Neuromuscular Disorders
Inability to recognise disgust as first cognitive symptom of ALS
Pathogenic T-cell signature identified in myasthenia gravis
Parkinson’s Disease
Levodopa-carbidopa intestinal gel in patients with advanced PD
New Frontier – Navigated Transcranial Ultrasound
Exploring the possibilities
Related Articles
August 18, 2021
Pregnant migraine patients at higher risk of complications
August 18, 2021
Alemtuzumab in treatment-naïve patients with aggressive MS
August 18, 2021
Eptinezumab shows acute benefits during migraine attack
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com